Skip to main content
  • Pipeline
    • Overview
      • Dovitinib
      • Stenoparib
      • Ixempra®
      • Additional Programs
    • Clinical Trials
  • Technology
    • The DRP® Method
    • Scientific Publications
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Investors
  • Contact
    • General Inquires
  • Careers
    • Join Allarity
Menu
  • Pipeline
    • Overview
      • Dovitinib
      • Stenoparib
      • Ixempra®
      • Additional Programs
    • Clinical Trials
  • Technology
    • The DRP® Method
    • Scientific Publications
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Investors
    • Overview
    • News
    • Stock Info
    • Financials
    • Governance
    • Resources
  • Contact
    • General Inquires
  • Careers
    • Join Allarity
  • Overview
    • News
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
      • Analyst Coverage
    • Financials
      • Annual Reports
      • SEC Filings
    • Governance
      • Governance Documents
      • Executive Management
      • Board of Directors
      • Committee Composition
    • Resources
      • Investor Email Alerts
      • Investor Contacts
    • Presentations
Site Search

Executive Management

  • Overview
    • News
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
      • Analyst Coverage
    • Financials
      • Annual Reports
      • SEC Filings
    • Governance
      • Governance Documents
      • Executive Management
      • Board of Directors
      • Committee Composition
    • Resources
      • Investor Email Alerts
      • Investor Contacts
    • Presentations

Executive Management Carousel

Portrait

James G. Cullem, Chief Executive Officer

James G. Cullem has been the Chief Executive Officer (interim) of Allarity Therapeutics, Inc. since June 2022, a director of ours since July 2022, and has been a part of the Company’s senior management team since 2014. He most recently served as the Company’s Chief Business Officer, and previously served as its Senior Vice President, Corporate Development (including the Company' predecessors, Allarity Therapeutics A/S and Oncology Venture A/S). He brings 20+ years of diverse experience in life sciences organizational management, business development & licensing, intellectual property & technology transfer/commercialization, alliance management, and strategic planning as a member of executive teams. During his tenure, Mr. Cullem has been responsible for the identification and acquisition of most of our lead clinical oncology assets, including big pharma therapeutics dovitinib (from Novartis) and stenoparib (from Eisai). He leads the company’s global business and strategic development efforts, and played an instrumental role in the Company’s restructuring and re-focus of its clinical pipeline in 2019 and its migration to the U.S. Nasdaq in 2021. Mr. Cullem has experience in designing and negotiating a broad span of life science deals, has founded and led several early-stage biotech companies, and is a catalyst for businesses taking the next step in the fields of precision medicine and predictive/companion diagnostics, novel drug targets, proteomics and genomics, and clinical-stage cancer therapeutic development. Prior to Allarity, he served as part of the executive management teams of Enzymatics, Inc. and Cell Signaling Technology, Inc. and started his scientific career conducting bench research in virology and diagnostics at Chiron Corporation and the J. David Gladstone Institutes.He holds a B.S. degree in Biochemistry from The University of California at Davis, a Juris Doctorate (JD) degree from The University of New Hampshire Franklin Pierce School of Law, specializing in patent & I.P. law, and is a registered patent attorney before the United States Patent & Trademark Office.

Portrait

Joan Y. Brown, Chief Financial Officer

Ms. Brown has served as CFO (interim) since June 2022. Previously, Ms. Brown served as the Company’s Director of Financial Reporting, a position she has held since 2021, where she assisted in the Company’s move to the U.S. Nasdaq. She brings 20+ years of financial and regulatory reporting and audit experience, including full cycle accounting, payroll, management, and Board reporting. Prior to joining Allarity, Ms. Brown served as a consultant to a range of public and private companies providing financial reporting and regulatory compliance services (including companies with assets and sales of >$500 million), and as Director of Prudential Supervision at the Financial Institutions Commission (FICOM) (Vancouver, BC, Canada). Ms. Brown is a registered Certified Public Accountant (CPA), a Chartered Accountant (Canada) and holds a bachelor’s degree in Business Administration from Simon Frasier University.

Portrait

Marie Foegh, Chief Medical Officer

Marie Foegh has been the Chief Medical Officer of our predecessor, Allarity Therapeutics A/S since January 2018 and continues to serve our Chief Medical Officer. Dr. Foegh previously served as Chief Medical Officer of our first U.S. subsidiary, 2X-Oncology, Inc. (later Oncology Venture US, Inc.) from 2016 to 2018. Dr. Foegh brings thirty years of experience in the pharmaceutical and biotechnology industries to our senior management team and has a strong track record leading successful clinical development of therapeutics, including regulatory and medical affairs. She is also Adjunct Clinical Professor at Georgetown University, Department of Medicine and Adjunct Professor at New York Medical College, Department of Pharmacology. Dr. Foegh was the Chief Medical Officer and cofounder of Ell Imaging, LLC, an ultrasound device company, from 2014 to 2016. She serves as the Chair of the Board of Directors at the device company Injecto A/S since 2014. Dr. Foegh leads clinical development of our current precision medicine oncology pipeline, including our lead assets stenoparib, dovitinib, and Ixempra®. Dr. Foegh previously led the successful development and regulatory approval of more than 10 novel drug products in the U.S. and U.K., within oncology, endocrinology and cardiology. Dr. Foegh has fluency in regulatory interactions with the FDA and EMEA, including INDs, NDAs, IDEs (for predictive biomarkers and/or companion diagnostics), and product issues. She also manages interactions with the oncology key opinion leaders including our Scientific Advisory Board. Dr. Foegh holds both a Medical Doctorate (M.D.) degree and a Doctorate of Science (Dr.Sc.) degree from Copenhagen University, Denmark, and is a member of the American College of Physicians (ACP), American Medical Association (AMA), the American Society of Clinical Oncology, and the American College of Obstetricians and Gynecologists (ACOG).

Portrait

Steen Knudsen, Chief Scientific Officer, Founder

Steen Knudsen has been the Chief Scientific Officer of our predecessor since 2006 and continues to be our Chief Scientific Officer. Dr. Knudsen is a co-founder of Allarity Therapeutics A/S and the inventor of DRP®, the Drug Response Prediction Platform, which is our core technology and companion diagnostics platform. Dr. Knudsen is also a former Professor of Systems Biology with extensive expertise in mathematics, bioinformatics, biotechnology, and systems biology. He co-founded our predecessor in 2004 and served as its CEO from 2004 to 2006. Dr. Knudsen also previously served as a member on our predecessor’s Board of Directors from 2016 to 2020. In addition, Dr. Knudsen also currently serves as the Chief Executive Officer of MPI, Inc., our operating subsidiary in the U.S. Dr. Knudsen holds an M.Sc. degree in Engineering from the Technical University of Denmark and a Ph.D. degree in Microbiology from the University of Copenhagen. He received Postdoctoral training in computational biology from Harvard Medical School.

Portrait

Thomas Jensen, Senior Vice President of Investor Relations, Founder

Thomas H. Jensen has been the Senior Vice President, Investor Relations since June 2022, and a director of ours since July 2022. Mr. Jensen previously served as Senior Vice President, Information Technology of Allarity Therapeutics, Inc. as well as of our predecessor, Allarity Therapeutics A/S, since June 2020. Mr. Jensen previously served as the Chief Technology Officer of our predecessor from 2004 to June 2020. Mr. Jensen co-founded Allarity Therapeutics A/S in 2004. Mr. Jensen also established and currently leads our laboratories in Denmark. Alongside nurturing our global laboratories, Mr. Jensen is instrumental in building our investor relations operations, securing operational financing, and fostering the business growth of Allarity Therapeutics. Amongst Mr. Jensen’s accolades are his inventions of molecular biological guidelines combined with techniques for high quality reproducible RNA extraction and downstream processing. This allows for high resolution analysis of cancer patients’ biopsies. Mr. Jensen’s inventions are an important foundation of the DRP® -Drug Response Prediction platform. Mr. Jensen also currently serves on the Board of Cardeon AB, a Swedish company that invests in innovative Nordic companies and start-ups in medical technology and Life Science. Mr. Jensen holds a Bachelor of Science degree in Biology from the Technical University of Denmark, and conducted further studies in Biology at the University of Copenhagen.

Quick Links

  • SEC Filings

IR Contact

investorrelations@allarity.com

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Allarity Therapeutics, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Allarity Therapeutics to send you the requested Investor Email Alert updates.

* Required

*
Investor Alert Options
*





Unsubscribe

Email Alert Sign Up Confirmation

Pipeline
Overview
– Dovitinib
– Stenoparib
– Ixempra®
– Additional Programs
– Clinical Trials

Technology The DRP® Platform Scientific Publications

About Us
Overview
Leadership
Board of Directors
SAB
Partnering

Investors
Overview
News
Stock Info
Financials
Governance
Resources
Presentations

Newsroom
Top News
Media Contact

Contact
General Inquires

Careers
Join Allarity

Copyright © 2023 Allarity Therapeutics A/S. All Rights Reserved.

Unless otherwise specified, all product and service name appearing in this internet site are trademark owned by or licensed to Allarity, its subsidiaries or affiliates. No use of any Allarity trademark, trade name, or trade dress in this site may be made without the prior written authorization of Allarity, except to identify the product or services of company.

Terms of Use 

Privacy Policy

Social Media Policy

Cookie Policy
Allarity Therapeutics Logo

United States:
United States:
24 School Street, 2nd Floor,
Boston, MA 02108
USA
Tel. +1 401-426-4664

Denmark:
Venlighedsvej 1
2970 Hoersholm
Denmark
Tel. +45 88 74 24 14
CVR: 34623562